Leukemia treatment break: study tests pausing chemo for AML patients

NCT ID NCT06511882

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether people with acute myeloid leukemia (AML) who have been on a combination of azacitidine or decitabine plus venetoclax for a year can stop treatment if tests show no remaining cancer cells. Researchers want to see if these patients can stay in remission without the leukemia returning. The trial will enroll 37 adults whose AML is in remission with no detectable disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azacitidine or decitabine combined with venetoclax
What this could lead to: If successful, this could allow some AML patients to take a break from chemotherapy without their cancer coming back, improving quality of life.
What could go wrong: This is a small early-phase study with only 37 participants, so results may not apply to everyone. There is a risk that the leukemia could return after stopping treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.